News | March 17, 2026
BioDuro and Cenra API Solutions forge global API manufacturing joint venture in Taiwan
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
The trial will enroll up to 42 patients in Finland across four cohorts
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Subscribe To Our Newsletter & Stay Updated
